Previous 10 | Next 10 |
WOODCLIFF LAKE, N.J., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, President and Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will present at the...
Eagle Pharmaceuticals ( NASDAQ: EGRX ) announced Thursday that a federal appeals court ruled the company's blood pressure therapy vasopressin did not infringe on any of the patents claimed by Par Pharmaceutical, Inc., a unit of the generic drug maker Endo International ( END...
WOODCLIFF LAKE, N.J., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that the U.S. Court of Appeals for the Federal Circuit affirmed the U.S. District Court for the District of Delaware ...
Image source: The Motley Fool. Eagle Pharmaceuticals (NASDAQ: EGRX) Q2 2022 Earnings Call Aug 09, 2022 , 8:30 a.m. ET Operator Continue reading For further details see: Eagle Pharmaceuticals (EGRX) Q2 2022 Earnings Call Transcript
Eagle Pharmaceuticals, Inc. (EGRX) Q2 2022 Earnings Conference Call August 09, 2022 8:30 AM ET Company Participants Lisa Wilson – Investor Relations Scott Tarriff – President and Chief Executive Officer Mike Greenberg – Vice President-Medical...
Eagle Pharmaceuticals press release ( NASDAQ: EGRX ): Q2 Non-GAAP EPS of $1.56 misses by $1.80 . Revenue of $74.1M (+54.0% Y/Y) misses by $42.79M . For further details see: Eagle Pharmaceuticals Non-GAAP EPS of $1.56 misses by $1.80, revenue of $74.1M mis...
• Q2 2022 net loss was $(0.74) per basic and diluted share and adjusted non-GAAP net income was $1.58 per basic and $1.56 per diluted share • Total revenue for Q2 2022 was $74.1 million, compared to $48.1 million in Q2 2021, primarily reflecting product sales of ...
-- ENA-001 is currently in development for: post-operative respiratory depression, community drug overdose, and Apnea of Prematurity -- -- Approval for post-operative respiratory depression expected in 2026 and community drug overdose thereafter -- -- ENA-001 works peripherally by...
Eagle Pharmaceuticals ( NASDAQ: EGRX ) is scheduled to announce Q2 earnings results on Tuesday, August 9th, before market open. The consensus EPS Estimate is $3.36 (+261.3% Y/Y) and the consensus Revenue Estimate is $116.89M (+142.9% Y/Y). Over the last 2 years, EGRX ...
WOODCLIFF LAKE, N.J., July 28, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its 2022 second quarter financial results on Tuesday, August 9, 2022, before the market ope...
News, Short Squeeze, Breakout and More Instantly...
Eagle Pharmaceuticals Inc. Company Name:
EGRX Stock Symbol:
NASDAQ Market:
Eagle Pharmaceuticals Inc. Website:
2024-07-27 11:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-17 12:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-07 19:54:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...